Retrospective 4,017 coronary artery disease patients hospitalized for COVID-19 in the USA, showing no significant difference in outcomes with low dose aspirin use.
|
risk of death, 37.0% lower, RR 0.63, p = 0.28.
|
|
risk of ICU admission, 1.0% higher, RR 1.01, p = 0.79.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Zadeh et al., 20 Dec 2022, retrospective, USA, peer-reviewed, mean age 62.2, 8 authors.
IMPACT OF OACS ON OUTCOMES OF COVID-19 INFECTION IN OLDER ADULTS WITH HISTORY OF ATRIAL FIBRILLATION
Ricardo Criado Carrero, Andrew Carl Crawford, Ali Vaeli Zadeh, Alan Wong, Ana De, Diego Diaz, Elias Collado, Joshua Larned, Amy Ai, Crim Sabuncu, Ali Vaeli Zadeh, Ricardo Criado Carrero, Noah Mandile, Marina Stukova, German Lopez, Holy Cross
diseases. Records from both groups were reviewed for the first episode of HF over 12 months following the initiation of treatment. Pearson's chi-squared test was used to compare groups. The strength of association was reported using Risk Ratios (RR). A p-value < 0.05 was deemed significant. Results: 6,446 were included in each group. The mean age, gender and ECI were indifferent. 958 (15%) of patients treated with AADs and 987 (15.3%) of patients treated with CA had a first episode of HF over a year after the treatment which was not significantly different between groups (RR=1.03, CI95% = 0.95-1.11, p=0.49). Conclusion: The modality of treatment after the first episode of AF in older population doesn't significantly affect the risk of HF over the first year.
